![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Celgene Settles Patent Royalty Case for $198.5 Million
Celgene Settles Patent Royalty Case for $198.5 Million
February 23, 2017
Celgene will pay $198.5 million to settle a case alleging the company failed to pay royalties on patents covering the multiple myeloma drugs Revlimid and Pomalyst/Imnovid.
The settlement grants Celgene a royalty-free license to certain patent protections on the drugs and includes provisions for contingent royalties and other payments — although the company does not expect these payments will be triggered.
The deal resolves a 2013 lawsuit accusing Celgene of not paying royalties after the biotech firm received an extension on the patents for Revlimid and Pomalyst/Imnovid.
Upcoming Events
-
21Oct